EMEA-000574-PIP02-12-M02

  • Email
  • Help

Overview

Product details for Blincyto
Invented nameBlincyto
Active substance

Blinatumomab

Decision numberP/0401/2017
PIP numberEMEA-000574-PIP02-12-M02
Pharmaceutical form(s)Powder for solution for infusion
Condition(s)/indication(s)

Treatment of acute lymphoblastic leukaemia

Route(s) of administrationIntravenous use
PIP applicant

Amgen Europe B.V.
Tel. +44 (0)1223 420305
E-mail: pipenquiry@amgen.com

Decision typePM: decision on the application for modification of an agreed PIP

Decision